Covered recipient · General Payments record
SUZANNE REIM FANNING
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$122,626.62
138 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,135.00 | 22 |
| Consulting Fee | $16,983.75 | 10 |
| Travel and Lodging | $9,452.40 | 43 |
| Honoraria | $6,048.00 | 1 |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,405.00 | 2 |
| Food and Beverage | $2,502.48 | 59 |
| Education | $99.99 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $53,497.15 | 32 |
| Genmab U.S., Inc. | $19,902.87 | 43 |
| Takeda Pharmaceuticals U.S.A., Inc. | $13,096.97 | 9 |
| GENZYME CORPORATION | $9,582.21 | 4 |
| Blueprint Medicines Corporation | $7,725.33 | 8 |
| ADC Therapeutics America, Inc. | $4,809.10 | 6 |
| ABBVIE INC. | $3,850.59 | 5 |
| Janssen Biotech, Inc. | $3,639.99 | 4 |
| Janssen Scientific Affairs, LLC | $1,947.50 | 2 |
| CTI BioPharma Corp. | $1,725.00 | 1 |
| SERVIER PHARMACEUTICALS LLC | $1,680.00 | 1 |
| Incyte Corporation | $606.25 | 1 |
| Novartis Pharmaceuticals Corporation | $134.58 | 5 |
| Kite Pharma, Inc. | $121.14 | 1 |
| Celgene Corporation | $117.67 | 6 |
| Genentech USA, Inc. | $34.18 | 2 |
| Astellas Pharma US Inc | $27.03 | 1 |
| Acrotech Biopharma Inc. | $21.46 | 1 |
| Rigel Pharmaceuticals, Inc. | $20.95 | 1 |
| Pharmacyclics LLC, An AbbVie Company | $19.75 | 1 |
| JAZZ PHARMACEUTICALS INC. | $19.68 | 1 |
| Daiichi Sankyo Inc. | $18.71 | 1 |
| Foundation Medicine, Inc. | $15.61 | 1 |
| Karyopharm Therapeutics Inc. | $12.90 | 1 |
Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SUZANNE REIM FANNING
NPI 1568664480 · CMS profile ID 343154
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
GREENVILLE, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1568664480?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SUZANNE REIM FANNING, NPI 1568664480, CMS profile ID 343154. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568664480?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). SUZANNE REIM FANNING, NPI 1568664480, CMS profile ID 343154. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568664480?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- SUZANNE REIM FANNING, NPI 1568664480, CMS profile ID 343154, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1568664480?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
138 matching records · $122,626.62 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–138 of 138.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $17.14 | 06/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040572383 | CMS |
| Foundation Medicine, Inc. | $15.61 | 06/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1058794325 | CMS |
| ABBVIE INC. | $948.00 | 06/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997228881 | CMS |
| Karyopharm Therapeutics Inc. | $12.90 | 06/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056909681 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,570.00 | 06/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055385051 | CMS |
| Janssen Biotech, Inc. | $1,350.00 | 06/14/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988521675 | CMS |
| E.R. Squibb & Sons, L.L.C. | $265.93 | 06/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224623 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,964.00 | 06/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224639 | CMS |
| Genentech USA, Inc. | $17.04 | 06/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040572393 | CMS |
| E.R. Squibb & Sons, L.L.C. | $7,623.00 | 05/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224629 | CMS |
| Janssen Biotech, Inc. | $1,350.00 | 05/15/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988521669 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,964.00 | 05/10/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224593 | CMS |
| Celgene Corporation | $23.70 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224545 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,964.00 | 04/13/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224517 | CMS |
| Genmab U.S., Inc. | $4,040.00 | 04/07/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348607 | CMS |
| Celgene Corporation | $18.34 | 03/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224541 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,070.00 | 03/31/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224481 | CMS |
| Genmab U.S., Inc. | $17.56 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348601 | CMS |
| Genmab U.S., Inc. | $21.07 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348603 | CMS |
| Genmab U.S., Inc. | $15.92 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348609 | CMS |
| Genmab U.S., Inc. | $8.19 | 03/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348613 | CMS |
| Genmab U.S., Inc. | $494.64 | 03/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348615 | CMS |
| Genmab U.S., Inc. | $38.09 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348617 | CMS |
| Genmab U.S., Inc. | $32.00 | 03/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348619 | CMS |
| Genmab U.S., Inc. | $187.59 | 03/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348621 | CMS |
| Genmab U.S., Inc. | $112.57 | 03/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348623 | CMS |
| Genmab U.S., Inc. | $325.40 | 03/09/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348605 | CMS |
| Genmab U.S., Inc. | $110.75 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051348611 | CMS |
| E.R. Squibb & Sons, L.L.C. | $7,623.00 | 03/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224493 | CMS |
| E.R. Squibb & Sons, L.L.C. | $289.51 | 03/08/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224511 | CMS |
| Blueprint Medicines Corporation | $38.01 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051272189 | CMS |
| E.R. Squibb & Sons, L.L.C. | $189.35 | 02/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224499 | CMS |
| E.R. Squibb & Sons, L.L.C. | $124.67 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224505 | CMS |
| E.R. Squibb & Sons, L.L.C. | $131.00 | 02/08/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224445 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5,929.00 | 02/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224459 | CMS |
| ADC Therapeutics America, Inc. | $1,550.00 | 01/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053784719 | CMS |
| E.R. Squibb & Sons, L.L.C. | $125.42 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016224451 | CMS |
| ADC Therapeutics America, Inc. | $54.10 | 01/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053784713 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $293,215.14 | 28 |
| PY2024 | Principal investigator | $273,898.15 | 55 |
| PY2023 | Principal investigator | $266,899.65 | 53 |
| PY2022 | Principal investigator | $230,178.83 | 90 |
| PY2021 | Principal investigator | $440,992.35 | 115 |
| PY2020 | Principal investigator | $1,220,528.29 | 122 |
| PY2019 | Recipient | $19,291.50 | 3 |
| PY2019 | Principal investigator | $290,529.01 | 106 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
28 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $14,944.80 | 12/04/2025 | Covered Recipient Teaching Hospital GHS GREENVILLE MEMORIAL HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202411731 |
| Principal investigator 1 | ABBVIE INC. | $6,127.00 | 11/27/2025 | Covered Recipient Teaching Hospital GHS GREENVILLE MEMORIAL HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202411727 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,250.00 | 10/28/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212068026 |
| Principal investigator 1 | Kite Pharma, Inc. | $10,500.00 | 10/21/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212068021 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,762.40 | 10/01/2025 | Non-covered Recipient Entity Us Oncology Research | A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma | No dispute reported | 06/30/2026 | 1235992139 |
| Principal investigator 1 | Kite Pharma, Inc. | $10,500.00 | 10/01/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212068016 |
| Principal investigator 1 | Incyte Corporation | $97.08 | 09/09/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240481896 |
| Principal investigator 1 | Incyte Corporation | $58.78 | 09/09/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240481902 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 09/09/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240481910 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,115.00 | 07/22/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212071584 |
| Principal investigator 1 | Eli Lilly and Company | $623.61 | 06/11/2025 | Covered Recipient Teaching Hospital OCONEE MEMORIAL HOSPITAL | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187873361 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 06/04/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240481884 |
| Principal investigator 1 | Incyte Corporation | $17,700.00 | 06/04/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240481890 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,250.00 | 05/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212071580 |
| Principal investigator 1 | GENZYME CORPORATION | $20,537.00 | 04/14/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226080463 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute Spartanburg | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994501 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute Seneca | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994503 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute Grove Commons | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994505 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute Greer | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994507 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute Easley | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994509 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994511 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994513 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $271.00 | 03/26/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226085071 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,469.00 | 03/18/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212071576 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,064.00 | 02/15/2025 | Non-covered Recipient Entity Cancer Center Of The Carolinas | A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma | No dispute reported | 06/30/2026 | 1235998426 |
| Principal investigator 1 | Acerta Pharma LLC | $90.00 | 02/12/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185547125 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,250.00 | 02/04/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212071573 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,469.00 | 01/22/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212071568 |